First Dallas Securities Inc. decreased its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 2.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,128 shares of the company’s stock after selling 430 shares during the period. Johnson & Johnson makes up 1.9% of First Dallas Securities Inc.’s holdings, making the stock its 11th biggest position. First Dallas Securities Inc.’s holdings in Johnson & Johnson were worth $3,202,000 at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Lincoln Capital Corp increased its position in Johnson & Johnson by 15.9% during the 3rd quarter. Lincoln Capital Corp now owns 1,332 shares of the company’s stock worth $218,000 after buying an additional 183 shares during the period. Ieq Capital LLC increased its position in Johnson & Johnson by 5.1% during the 3rd quarter. Ieq Capital LLC now owns 128,012 shares of the company’s stock worth $20,912,000 after buying an additional 6,154 shares during the period. RFG Advisory LLC increased its position in Johnson & Johnson by 2.7% during the 3rd quarter. RFG Advisory LLC now owns 22,434 shares of the company’s stock worth $3,900,000 after buying an additional 594 shares during the period. Willis Investment Counsel increased its position in Johnson & Johnson by 0.4% during the 4th quarter. Willis Investment Counsel now owns 328,884 shares of the company’s stock worth $58,097,000 after buying an additional 1,358 shares during the period. Finally, Wambolt & Associates LLC grew its holdings in shares of Johnson & Johnson by 2.5% during the 4th quarter. Wambolt & Associates LLC now owns 14,528 shares of the company’s stock worth $2,566,000 after purchasing an additional 355 shares in the last quarter. Institutional investors own 67.94% of the company’s stock.
Analysts Set New Price Targets
Several analysts have recently issued reports on the company. Piper Sandler reduced their target price on Johnson & Johnson from $55.00 to $52.00 in a report on Monday, February 6th. UBS Group assumed coverage on Johnson & Johnson in a report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 target price on the stock. StockNews.com assumed coverage on Johnson & Johnson in a report on Thursday, March 16th. They set a “strong-buy” rating on the stock. Atlantic Securities reduced their target price on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a report on Wednesday, April 19th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, February 1st. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $173.00.
Johnson & Johnson Price Performance
Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.51 by $0.17. Johnson & Johnson had a return on equity of 35.53% and a net margin of 13.22%. The company had revenue of $24.75 billion during the quarter, compared to the consensus estimate of $23.61 billion. During the same period last year, the company earned $2.67 earnings per share. The firm’s revenue was up 5.6% compared to the same quarter last year. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.66 earnings per share for the current year.
Johnson & Johnson Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be issued a $1.19 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 dividend on an annualized basis and a yield of 2.91%. The ex-dividend date is Monday, May 22nd. Johnson & Johnson’s payout ratio is presently 94.56%.
Insiders Place Their Bets
In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of Johnson & Johnson stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the completion of the sale, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.20% of the stock is currently owned by corporate insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Read More
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Insiders Drive Volatility For Keurig Dr Pepper
- After a 40% Drop, Analysts Remain Bullish on Impinj
- Visa Charges Higher After Better-Than-Expected Q2 Report
- onsemi Puts A Bottom in Chip Stocks, Heads For New Highs
- Can Teladoc Stock Be Resuscitated?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
